1.
2.
Daily pill can double survival time for deadliest cancer, trial shows
(news.ycombinator.com)
3.
Triomics nabs $22M to bring oncology-specific AI to cancer centers
(techcrunch.com)
4.
Early-onset cancer fuels calls for wider screening — but at what cost?
(feeds.nature.com)
5.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
(feeds.content.dowjones.io)
6.
Engaging the head and the heart: why scientists turn to poetry
(feeds.nature.com)
7.
AstraZeneca’s Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer
(feeds.content.dowjones.io)